A Phase 2, Open-label Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTRSC in Patients With Transthyretin (TTR) Cardiac Amyloidosis Who Have Previously Received ALN-TTRSC

Trial Profile

A Phase 2, Open-label Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTRSC in Patients With Transthyretin (TTR) Cardiac Amyloidosis Who Have Previously Received ALN-TTRSC

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 May 2017

At a glance

  • Drugs Revusiran (Primary)
  • Indications Amyloidosis; Cardiomyopathies
  • Focus Adverse reactions
  • Sponsors Alnylam Pharmaceuticals
  • Most Recent Events

    • 10 Oct 2016 Dosing discontinued; Follow-up of patients for safety
    • 18 Jul 2016 Planned End Date changed from 1 May 2017 to 1 Mar 2017.
    • 18 Jul 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Feb 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top